17 Capital Partners LLC Purchases 121 Shares of Axon Enterprise, Inc $AXON

17 Capital Partners LLC increased its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 7.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,739 shares of the biotechnology company’s stock after acquiring an additional 121 shares during the period. Axon Enterprise comprises 0.8% of 17 Capital Partners LLC’s holdings, making the stock its 28th largest holding. 17 Capital Partners LLC’s holdings in Axon Enterprise were worth $1,440,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in AXON. TCTC Holdings LLC increased its stake in shares of Axon Enterprise by 75.0% in the 1st quarter. TCTC Holdings LLC now owns 56 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 24 shares during the last quarter. Banque Transatlantique SA acquired a new stake in Axon Enterprise in the first quarter valued at about $31,000. Flaharty Asset Management LLC bought a new position in Axon Enterprise in the first quarter valued at about $33,000. Hemington Wealth Management grew its position in Axon Enterprise by 70.8% in the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares during the last quarter. Finally, Whipplewood Advisors LLC raised its stake in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 27 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AXON has been the topic of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and issued a $870.00 price target on shares of Axon Enterprise in a research note on Wednesday, September 24th. Wall Street Zen lowered shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $825.00 price target on shares of Axon Enterprise in a report on Monday, September 29th. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Finally, Royal Bank Of Canada initiated coverage on Axon Enterprise in a research report on Monday. They set an “outperform” rating and a $860.00 price objective on the stock. Fifteen analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $814.00.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $531.09 on Thursday. The firm has a market cap of $41.91 billion, a PE ratio of 131.13, a price-to-earnings-growth ratio of 29.49 and a beta of 1.45. The firm’s fifty day moving average is $690.64 and its 200-day moving average is $733.23. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.45 earnings per share. Sell-side analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Jeri Williams sold 100 shares of the company’s stock in a transaction that occurred on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at $1,065,596.64. This represents a 6.60% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Brittany Bagley sold 5,000 shares of the stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $713.88, for a total transaction of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at $66,813,456.96. This represents a 5.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 38,622 shares of company stock valued at $26,439,364 in the last ninety days. Insiders own 4.40% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.